title: Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
abstract: OBJECTIVE
  To compare the short-term effects of rosuvastatin and simvastatin on insulin-resistance and endothelial dysfunction in middle-aged patients with type 2 diabetes and mild untreated dyslipidemia.
  
  
  METHODS
  29 Subjects randomly assigned to rosuvastatin 20mg/daily or simvastatin 20mg/daily for 4 weeks. Following data collected both pre- and post-treatment: fasting glucose, lipids, hs CRP, TNF-alpha, insulin sensitivity measured with euglycemic-hyperinsulinemic clamp and flow-mediated dilation with brachial artery reactivity technique.
  
  
  RESULTS
  Both treatments markedly reduced LDL cholesterol (p<0.001 for both). Insulin sensitivity did not change from relative baseline values in both groups, as well as fasting glucose and adiponectin. Simvastatin significantly improved flow-mediated dilation (p<0.01), to a greater extent than in patients taking rosuvastatin (p=0.09). We found no association between flow-mediated dilation improvement, LDL reduction and changes in hs CRP levels.
  
  
  CONCLUSIONS
  In type 2 diabetic individuals rosuvastatin was less effective than simvastatin at improving endothelium-dependent vasodilation within one month, without affecting insulin-resistance, adiponectin levels and inflammation.
authors.affiliation: Department of Internal Medicine, University of Rome Tor Vergata, Via Montpellier,1, I-00133 Rome, Italy.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Bellia
authors.forename: Stefano
authors.initials: S
authors.lastname: Rizza
authors.forename: Angelica
authors.initials: A
authors.lastname: Galli
authors.forename: Rossella
authors.initials: R
authors.lastname: Fabiano
authors.forename: Giulia
authors.initials: G
authors.lastname: Donadel
authors.forename: Marco Felice
authors.initials: MF
authors.lastname: Lombardo
authors.forename: Carmine
authors.initials: C
authors.lastname: Cardillo
authors.forename: Paolo
authors.initials: P
authors.lastname: Sbraccia
authors.forename: Manfredi
authors.initials: M
authors.lastname: Tesauro
authors.forename: Davide
authors.initials: D
authors.lastname: Lauro
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000187:drug effects; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014664:Vasodilation / Q000187:drug effects
chemical_list: D052242:Adiponectin; D001786:Blood Glucose; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011743:Pyrimidines; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein; D019821:Simvastatin